SitemapImprintDatenschutzerklärungdeutschenglish
MHH Logo

PROBASE

 

In the PROBASE study (Risk-adapted prostate cancer early detection study based on a “baseline” PSA value in young men – a prospective multicenter randomized trial) a modern concept of a general PSA-Screening will be investigated. However, the optimal age to begin a risk-adapted PSA screening with screening intervals according to the level of the individual baseline PSA value has never been evaluated in a prospective randomized trial. The present trial is the first randomized trial to prospectively evaluate the concept of a baseline PSA. Furthermore, it is the first trial to define the beginning of a risk-adapted screening either at age 45 or 50. In addition, this trial will evaluate subsequent risk-adapted screening intervals according to the level of the individual baseline PSA value.

 

Amount of probands:

 

  • 7451 probands (2017)

Samples:

  • Plasma           (31.900)
  • Sera               (90.500)
  • Urine              (17.500)
  • whole blood     (4.700)
  • Buffy coat      (15.100)


Temperatur of storage:

  • -196°C